Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00214773|
Recruitment Status : Unknown
Verified January 2019 by BioMarin Pharmaceutical.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : January 22, 2019
|Condition or disease|
|Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||MPS VI Clinical Surveillance Program (CSP)|
|Study Start Date :||July 2005|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||December 2020|
No intervention. This is an observational program.
- To further characterize the natural progression of MPS VI disease, irrespective of treatment modality and to evaluate efficacy and safety treatment with Galsulfase. [ Time Frame: at least 15 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214773
|Contact: MEDINFO MEDINFO||(615) 523-0310||MEDINFO@bmrn.com|
|Study Director:||Julie Johnson||BioMarin Pharmaceutical|